drugset / Trial / NCT04602013
Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell Carcinoma
Phase 2
Unknown
53 enrolled
Sichuan Cancer Hospital and Research Institute
Affiliated Hospital of Southwest Medical University · collabChongqing Three Gorges Central Hospital · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabGeneral Hospital of Ningxia Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
This study evaluated the effectiveness and safety of sintilimab combined with cCRT in patients with locally advanced ESCC.
Timeline
- Start
- 2020-10-11
- Primary completion
- 2022-05
- Completion
- 2022-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 180 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 220 mg/m2 | — |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | — |
| Subject | Sintilimab | Monoclonal antibody | 3 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 25 mg/m2 | Intravenous |